AON to Become Public Company Through Business Combination Agreement

American Oncology Network (AON) announced that they have entered into a definitive business combination agreement and will become a public company.

Fort Myers, Fla. & Los Angeles, October 6, 2022 – American Oncology Network, LLC (AON) announced that they have entered into a definitive business combination agreement with Digital Transformation Opportunities Corp. (DTOC) pursuant to which AON will become a public company (the “Business Combination”).

Upon the closing of the Business Combination, AON’s senior leadership team will continue to serve in their current roles. The combined company will be led by AON’s chief executive officer (CEO) Todd Schonherz, President and chief development officer Brad Prechtl, chief financial officer David Gould, and chief medical officer Dr Stephen "Fred" Divers. AON’s existing board, which is composed of practicing medical oncologists, is expected to remain in place and will be joined by additional members affiliated with DTOC.

“This transaction represents the next step in AON’s journey to become the leading platform for community-based oncology practices. Since launching the AON platform in 2018, we’ve been able to drive consistently strong growth by providing our physician partners with a strong suite of practice management tools and ancillary services as well as access to the financial benefits associated with being integrated with a scaled platform," said AON CEO Todd Schonherz.

"We look forward to continuing to grow our network of physician partners and supporting them with our physician practice management platform.”

Learn more.

Related Videos
Dr Ajay Goel
Dr Ajay Goel
Julie Patterson, PharmD, PhD
Neil Goldfarb, CEO, Greater Philadelphia Business Coalition on Health
Screenshot of Fran Gregory, PharmD, MBA, during a video interview
Yael Mauer, MD, MPH
Pregnant Patient | image credit: pressmaster -
Dr Julie Patterson, National Pharmaceutical Council
Diana Isaacs, PharmD
Beau Raymond, MD
Related Content
CH LogoCenter for Biosimilars Logo